Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)”

121 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 121 results

Large-scale testing (Phase 3)Study completedNCT00400478
What this trial is testing

A Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment Versus Observation in Patients With Aggressive B-cell Lymphoma: NHL-13

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular NHL Grade 3b
Arbeitsgemeinschaft medikamentoese Tumortherapie 683
Early research (Phase 1)Study completedNCT05665530
What this trial is testing

PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies

Who this might be right for
Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Mantle Cell Lymphoma (MCL)+9 more
Prelude Therapeutics 86
Early research (Phase 1)Study completedNCT00243087
What this trial is testing

Investigation of Safety, Tolerability and Maximum Tolerated Dose (MTD) of BI 2536 in Patients With Recurrent Advanced Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma
Boehringer Ingelheim 41
Not applicableActive Not RecruitingNCT02633111
What this trial is testing

DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
B-cell Non-Hodgkin LymphomaAggressive
Memorial Sloan Kettering Cancer Center 501
Testing effectiveness (Phase 2)Active Not RecruitingNCT06093841
What this trial is testing

Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL

Who this might be right for
Lymphoma, Large B-Cell, DiffuseFollicular Lymphoma Grade 3BHigh-grade B-cell Lymphoma+1 more
Shanghai Ming Ju Biotechnology Co., Ltd. 46
Large-scale testing (Phase 3)Ended earlyNCT01232556
What this trial is testing

Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Who this might be right for
Lymphoma, Non-Hodgkin
Pfizer 338
Early research (Phase 1)Ended earlyNCT00538187
What this trial is testing

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Who this might be right for
Adult Non-Hodgkin LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Grade 1 Follicular Lymphoma+5 more
National Cancer Institute (NCI) 18
Testing effectiveness (Phase 2)Study completedNCT01527045
What this trial is testing

Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

Who this might be right for
Aggressive Non-Hodgkin LymphomaBlasts Under 5 Percent of Bone Marrow Nucleated CellsChronic Lymphocytic Leukemia+18 more
Fred Hutchinson Cancer Center 47
Not applicableActive Not RecruitingNCT01787409
What this trial is testing

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Who this might be right for
Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell Lymphoma+12 more
Mayo Clinic 565
Testing effectiveness (Phase 2)Active Not RecruitingNCT03038672
What this trial is testing

Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Who this might be right for
ALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma Activated B-Cell TypeDiffuse Large B-Cell Lymphoma Associated With Chronic Inflammation+32 more
National Cancer Institute (NCI) 54
Post-approval studies (Phase 4)UnknownNCT04152577
What this trial is testing

R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL

Who this might be right for
Lymphoma, B-Cell
Shandong Provincial Hospital 200
Large-scale testing (Phase 3)Study completedNCT00004112
What this trial is testing

Combination Chemotherapy With or Without Rituximab in Treating Patients With Newly Diagnosed Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
University of Nebraska
Testing effectiveness (Phase 2)Looking for participantsNCT06534437
What this trial is testing

MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)

Who this might be right for
Non-Hodgkin Lymphoma, B-cell
Ryvu Therapeutics SA 178
Early research (Phase 1)Study completedNCT03003546
What this trial is testing

Nab-paclitaxel/Rituximab-coated Nanoparticle AR160 in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial

Who this might be right for
Recurrent Aggressive Non-Hodgkin LymphomaRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Small Lymphocytic Lymphoma+3 more
Mayo Clinic 9
Testing effectiveness (Phase 2)Study completedNCT01851551
What this trial is testing

Phase 1/2 Study of VSLI Plus Rituximab in Patients With Relapsed and/or Refractory NHL

Who this might be right for
Non-Hodgkin's LymphomaDiffuse Large B-cell LymphomaMantle Cell Lymphoma
Acrotech Biopharma Inc. 22
Testing effectiveness (Phase 2)Ended earlyNCT04161118
What this trial is testing

TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
Non Hodgkin Lymphoma
University of Cologne 3
Large-scale testing (Phase 3)Study completedNCT03575351
What this trial is testing

Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Who this might be right for
Lymphoma, Non-Hodgkin
Celgene 184
Large-scale testing (Phase 3)Study completedNCT03366272
What this trial is testing

Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma Patients

Who this might be right for
Lymphoma, Non-Hodgkin
Universität des Saarlandes 348
Testing effectiveness (Phase 2)Ended earlyNCT00290706
What this trial is testing

A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Northwestern University 32
Large-scale testing (Phase 3)Looking for participantsNCT06230224
What this trial is testing

A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin Lymphoma (B-NHL)
Regeneron Pharmaceuticals 216
Load More Results